Synergy Pharmaceuticals (SGYP) Reaches $2.15 After 9.00% Down Move; Fiduciary Trust Company Has Boosted Its Halliburton Co (HAL) Stake

November 14, 2017 - By Dolores Ford

The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! About 8.48M shares traded or 28.10% up from the average. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since November 14, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.The move comes after 7 months negative chart setup for the $483.65 million company. It was reported on Nov, 14 by Barchart.com. We have $1.96 PT which if reached, will make NASDAQ:SGYP worth $43.53 million less.

Fiduciary Trust Company increased Halliburton Co (HAL) stake by 15.59% reported in 2017Q2 SEC filing. Fiduciary Trust Company acquired 13,836 shares as Halliburton Co (HAL)’s stock declined 11.04%. The Fiduciary Trust Company holds 102,577 shares with $4.38 million value, up from 88,741 last quarter. Halliburton Co now has $37.91 billion valuation. The stock declined 1.73% or $0.76 reaching $43.45 on the news. About 1.69M shares traded. Halliburton Company (NYSE:HAL) has risen 19.03% since November 14, 2016 and is uptrending. It has outperformed by 2.33% the S&P500.




Fiduciary Trust Company decreased Vanguard Whitehall Fds (VYM) stake by 9,782 shares to 63,429 valued at $4.96M in 2017Q2. It also reduced Simon Ppty Group Inc New (NYSE:SPG) stake by 2,759 shares and now owns 101,931 shares. Berkshire Hathaway Inc Del Cl B (BRKB) was reduced too.

Among 38 analysts covering Halliburton Company (NYSE:HAL), 34 have Buy rating, 0 Sell and 4 Hold. Therefore 89% are positive. Halliburton Company had 131 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Guggenheim given on Tuesday, June 27. The firm has “Buy” rating given on Friday, September 1 by RBC Capital Markets. The rating was maintained by FBR Capital with “Outperform” on Wednesday, February 22. The stock of Halliburton Company (NYSE:HAL) has “Buy” rating given on Friday, February 19 by DA Davidson. Argus Research maintained Halliburton Company (NYSE:HAL) on Thursday, May 19 with “Buy” rating. The rating was maintained by Barclays Capital on Thursday, October 20 with “Overweight”. The stock has “Buy” rating by UBS on Tuesday, January 26. The firm has “Buy” rating by BMO Capital Markets given on Wednesday, June 7. The firm earned “Buy” rating on Thursday, May 19 by Griffen Securities. Deutsche Bank maintained Halliburton Company (NYSE:HAL) rating on Wednesday, April 6. Deutsche Bank has “Buy” rating and $40 target.

Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.14, from 1.08 in 2017Q1. It is negative, as 96 investors sold HAL shares while 307 reduced holdings. 77 funds opened positions while 301 raised stakes. 681.00 million shares or 0.74% more from 675.98 million shares in 2017Q1 were reported. Nuance Ltd Llc stated it has 71,305 shares. Nippon Life Ins holds 0.03% of its portfolio in Halliburton Company (NYSE:HAL) for 35,333 shares. Tradition Limited Liability Company holds 13,310 shares or 0.19% of its portfolio. Court Place Limited Liability reported 54,176 shares or 1.1% of all its holdings. Advisor Prtnrs Ltd Llc holds 13,525 shares or 0.14% of its portfolio. Amg Natl Trust Bancorp stated it has 0.13% in Halliburton Company (NYSE:HAL). Hugh Johnson Advsrs Ltd Liability Corp owns 60,272 shares. Capital Guardian invested 0.45% of its portfolio in Halliburton Company (NYSE:HAL). Reinhart Prns has invested 0.05% in Halliburton Company (NYSE:HAL). Skylands Capital Ltd Llc, Wisconsin-based fund reported 120,375 shares. Stifel Fincl invested in 530,805 shares or 0.08% of the stock. California Public Employees Retirement Systems accumulated 0.13% or 1.94 million shares. Tocqueville Asset Management Lp has 0.12% invested in Halliburton Company (NYSE:HAL) for 229,540 shares. Robeco Institutional Asset Mngmt Bv invested in 0.05% or 184,332 shares. Cranbrook Wealth Mgmt Limited Liability Co invested in 0.02% or 997 shares.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Synergy Pharmaceuticals had 31 analyst reports since August 25, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, November 9 by Cantor Fitzgerald. The firm has “Buy” rating given on Monday, May 9 by Rodman & Renshaw. The rating was initiated by Oppenheimer with “Outperform” on Thursday, January 5. Cantor Fitzgerald maintained it with “Buy” rating and $11.0 target in Wednesday, September 27 report. Cantor Fitzgerald maintained Synergy Pharmaceuticals Inc (NASDAQ:SGYP) rating on Wednesday, June 7. Cantor Fitzgerald has “Buy” rating and $1100 target. Citigroup maintained the shares of SGYP in report on Wednesday, March 16 with “Neutral” rating. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned “Buy” rating by Rodman & Renshaw on Friday, January 20. Oppenheimer maintained it with “Buy” rating and $900 target in Thursday, August 10 report. The rating was downgraded by Citigroup on Friday, December 18 to “Neutral”. The firm earned “Buy” rating on Wednesday, May 31 by BTIG Research.

Investors sentiment decreased to 1.49 in 2017 Q2. Its down 0.45, from 1.94 in 2017Q1. It dropped, as 31 investors sold Synergy Pharmaceuticals Inc shares while 22 reduced holdings. 20 funds opened positions while 59 raised stakes. 158.68 million shares or 6.77% more from 148.62 million shares in 2017Q1 were reported. Creative Planning holds 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) or 151,705 shares. Jefferies Lc accumulated 45,000 shares. Cornerstone Cap Mngmt Hldg Limited Liability Company owns 133,159 shares. 185,874 were accumulated by Wells Fargo & Mn. Timessquare Mgmt Limited Co holds 0.07% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) or 2.57M shares. Citadel Advisors Ltd Liability Company reported 0.02% stake. Janney Montgomery Scott Limited Co reported 35,500 shares stake. Clear Harbor Asset Mngmt Limited Liability Company holds 0.26% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 303,060 shares. Prudential Incorporated stated it has 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Nationwide Fund Advisors holds 0.01% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) or 312,811 shares. Parametric Assocs Ltd Liability Company stated it has 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Valley National Advisers Inc holds 4,000 shares. Tiaa Cref Mngmt Limited Liability Co has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Equitec Specialists Limited Liability Co invested in 0% or 3,000 shares. D E Shaw owns 46,659 shares.

Since May 26, 2017, it had 2 insider buys, and 0 sales for $43,302 activity. BRANCACCIO JOHN P bought $23,335 worth of stock or 6,500 shares. JACOB GARY S had bought 5,680 shares worth $19,967 on Friday, May 26.

Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies. The company has market cap of $483.65 million. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. It currently has negative earnings. The Firm is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.